Free Trial
NYSE:ATNM

Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

Actinium Pharmaceuticals logo
$1.43 +0.01 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$1.44 +0.01 (+0.42%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Actinium Pharmaceuticals Stock (NYSE:ATNM)

Key Stats

Today's Range
$1.40
$1.49
50-Day Range
$1.35
$1.94
52-Week Range
$1.03
$8.64
Volume
202,954 shs
Average Volume
523,203 shs
Market Capitalization
$44.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Moderate Buy

Company Overview

Actinium Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

ATNM MarketRank™: 

Actinium Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 442nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Actinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Actinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Actinium Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Actinium Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Actinium Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Actinium Pharmaceuticals has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.88% of the float of Actinium Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Actinium Pharmaceuticals has recently decreased by 25.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Actinium Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Actinium Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.88% of the float of Actinium Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Actinium Pharmaceuticals has recently decreased by 25.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Actinium Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Actinium Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    Only 6 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.00% of the stock of Actinium Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.

  • Read more about Actinium Pharmaceuticals' insider trading history.
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Stock News Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More Headlines

ATNM Stock Analysis - Frequently Asked Questions

Actinium Pharmaceuticals' stock was trading at $1.26 at the beginning of the year. Since then, ATNM shares have increased by 13.5% and is now trading at $1.43.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) released its earnings results on Monday, August, 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02.

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020.The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Global Ship Lease (GSL), OPKO Health (OPK), Fitbit (FIT) and OHR Pharmaceutical (OHRP).

Company Calendar

Last Earnings
8/05/2024
Today
7/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ATNM
Previous Symbol
NYSE:ATNM
CIK
1388320
Web
N/A
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$2.00
Potential Upside/Downside
+174.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$48.82 million
Pretax Margin
-50,512.35%

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
1.11

Miscellaneous

Free Float
29,324,000
Market Cap
$45.39 million
Optionable
Optionable
Beta
-0.32
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NYSE:ATNM) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners